High-Altitude Pulmonary Edema

High-altitude pulmonary edema (HAPE) is a non-cardiogenic accumulation of fluid in the lungs that develops in susceptible people within days of rapid ascent to high altitude, presenting with breathlessness, cough, and reduced exercise tolerance. It is the most common cause of death from altitude illness and arises from an exaggerated rise in pulmonary artery pressure under hypoxia, distinguishing it from the cerebral forms of altitude illness.

Definition

High-altitude pulmonary edema is a non-cardiogenic pulmonary edema occurring in otherwise healthy individuals after recent ascent to high altitude, driven by hypoxia-induced pulmonary hypertension with increased pulmonary microvascular pressure and fluid leak into the alveoli.

Scope

This topic covers the pulmonary manifestation of altitude illness: its pathophysiology centered on hypoxic pulmonary vasoconstriction, recognized risk factors, susceptibility, and the evidence base behind its prevention. It is framed as a reference account of how the condition is defined and studied, not as treatment guidance, and it is distinguished from acute mountain sickness and high-altitude cerebral edema, which are treated under a separate topic.

Core questions

• Why does hypoxia cause pulmonary edema in some travelers but not others?
• How does exaggerated hypoxic pulmonary vasoconstriction lead to alveolar fluid leak?
• Which ascent and host factors predict HAPE susceptibility?
• What is the evidence basis for pharmacological prevention of HAPE?

Key concepts

• Hypobaric hypoxia
• Hypoxic pulmonary vasoconstriction
• Pulmonary hypertension
• Uneven (non-uniform) vasoconstriction
• Capillary stress failure
• HAPE susceptibility
• Non-cardiogenic pulmonary edema

Mechanisms

Hypoxia triggers pulmonary vasoconstriction; in people susceptible to HAPE this hypoxic pulmonary vasoconstriction is exaggerated and spatially uneven, so blood is overperfused through unconstricted vascular regions at high pressure. The resulting elevation of pulmonary microvascular pressure causes capillary stress failure, with leakage of fluid and protein into the alveoli that is non-cardiogenic in origin (Swenson & Bärtsch, 2012). Impaired alveolar fluid clearance and individual differences in the pulmonary vascular response contribute to susceptibility (Swenson & Bärtsch, 2012). The pivotal role of pulmonary artery pressure is supported by the demonstration that pulmonary vasodilation can reduce HAPE incidence in susceptible individuals (Bärtsch et al., 1991).

Clinical relevance

HAPE is the principal cause of altitude-related death and is therefore central to counseling susceptible travelers and planning ascent profiles, since its onset can be rapid once it begins. This entry explains how the condition is defined and understood as a basis for study; it does not provide diagnostic thresholds, drug dosing, or individualized treatment advice.

Epidemiology

HAPE occurs in a minority of those ascending rapidly to high altitude, with incidence rising with faster ascent, higher altitude attained, cold, and exertion, and with a strong tendency to recur in susceptible individuals (Swenson & Bärtsch, 2012; Hackett & Roach, 2001). A prior episode is the strongest predictor of future HAPE, defining a recognizably susceptible subgroup (Bärtsch et al., 1991).

Evidence & guidelines

The landmark randomized trial by Bärtsch and colleagues (1991) showed that pulmonary vasodilation could reduce HAPE incidence in susceptible mountaineers, establishing the centrality of pulmonary artery pressure to the disease. Swenson and Bärtsch (2012) provide a comprehensive physiological review, and the Wilderness Medical Society's 2019 clinical practice guidelines give graded recommendations for the prevention and treatment of HAPE alongside the other altitude illnesses (Luks et al., 2019).

History

Pulmonary edema at altitude was historically confused with pneumonia or heart failure until mid-twentieth-century reports recognized it as a distinct non-cardiogenic entity in healthy lowlanders ascending rapidly. Subsequent physiological work identified exaggerated hypoxic pulmonary vasoconstriction as central, and controlled prevention trials, beginning with the demonstration that vasodilation lowers HAPE incidence in susceptible people, anchored the modern understanding (Bärtsch et al., 1991; Swenson & Bärtsch, 2012).

Debates

What is the relative contribution of capillary stress failure versus impaired fluid clearance?

Whether HAPE is primarily a pressure-driven mechanical leak from capillary stress failure or also reflects deficient alveolar fluid reabsorption has been a focus of physiological investigation.

Key figures

• Peter Bärtsch
• Erik Swenson
• Peter Hackett
• Marco Maggiorini
• Oswald Oelz

Seminal works

• bartsch-1991
• swenson-bartsch-2012
• hackett-roach-2001

Frequently asked questions

How does high-altitude pulmonary edema differ from heart failure?

HAPE is a non-cardiogenic pulmonary edema, meaning the fluid accumulates because of hypoxia-driven pulmonary hypertension and capillary leak in otherwise healthy lungs, rather than because of left-heart failure raising pressure backward into the lungs.

Why are some people prone to high-altitude pulmonary edema and others not?

Susceptible individuals mount an exaggerated and uneven pulmonary vasoconstrictor response to hypoxia, raising pulmonary microvascular pressure; a previous episode is the strongest known predictor of recurrence.